Welcome to the e-CCO Library!

P391: Are cut-off ranges of Infliximab serum levels in Crohn’s disease always the same in clinical practice?
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

T. Valdes Delgado1, M. Guerra Veloz*1, M. Belvis Jimenez1, B. Maldonado Pérez1, L. Castro Laria1, A. Benítez Roldán1, R. Perea Amarillo1, V. Merino Bohorquez2, M. A. Calleja Hernandez2, T. Ortiz3, A. Caunedo Álvarez1, A. Vilches Arenas4, A. Saez Diaz5, F. Argüelles-Arias1

Created: Friday, 22 February 2019, 9:41 AM
P391: Differential use of vedolizumab in ulcerative colitis and Crohn's disease. Real life results from 2 tertiary referral centres in the United Kingdom
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Kamperidis N.*1, Cavazza A.2, Wahed M.2, Arebi N.1

Created: Wednesday, 20 February 2019, 10:36 AM
P391: Gender differences in adalimumab continuation rates: Results of a Crohn’s disease cohort
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Lie*, J. Kreijne, J. van der Woude

Created: Friday, 22 February 2019, 9:49 AM
P391: The availability of anti-TNF agents is associated with reduced early surgical requirements in Crohn’s disease but not in ulcerative colitis. A nationwide study from the Eneida registry
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Guasch1, A. Clos2, I. Ordás3,4, V. García-Sánchez5, J.P. Gisbert4,6, C. Taxonera7, I. Vera8, M. Mínguez9, J. Guardiola10, A. López-Sanromán11, M. Rivero-Tirado12, P. Nos13, F. Gomollón4,14, A.Y. Carbajo15, R. de Francisco16, M.D. Martín-Arranz17, E. Garcia-Planella18, S. García-López19, L. de Castro20, X. Calvet4,21, R. Camargo22, M. Esteve4,23, B. Sicilia24, M. Andreu25, A. Macho26, M. Piqueras27, F. Bermejo28, A. Gutiérrez29, D. Busquets30, P. Martínez-Montiel31, J. Hinojosa32, J.L. Pérez-Calle33, L. Bujanda34, A. Rodríguez-Pérez35, R. Lorente36, N. Jiménez37, M. Navarro-Llavat38, J.L. Cabriada39, P. Camo40, M. Van Domselaar41, E. Rodríguez-González42, C. Rodríguez-Gutiérrez43, J.M. Huguet44, A.J. Lucendo45, F. Argüelles46, P. Almela47, O. Merino48, M. Calafat49, M. Ogueta50, M. Charro51, J. Llaó52, C. Muñoz53, L. Ramos54, Á. Abad55, Ó. Roncero56, M. Barreiro-de-Acosta57, E. Sesé58, M. Mañosa2,4, E. Domènech2,4*

Created: Thursday, 21 February 2019, 9:14 AM
P391: Unpacking the different popular diets for pediatric Crohn's disease - concerns around nutritional adequacy
Year: 2022
Source: ECCO'22
Authors: Carmody , E.(1);Haskett , J.(1);Parkinson-McGraw , L.(1);Grover , Z.(1);Martinez , A.(1);Rashid , M.(1);Otley MD MSc FRCPC, A.(1);
Created: Friday, 11 February 2022, 3:52 PM
P392: A mobile application to monitor Inflammatory Bowel Disease patients during intravenous biologic treatment: Results of a feasibility study
Year: 2021
Source: ECCO'21 Virtual
Authors: Van Erp, L.W.(1);Groenen, M.J.M.(1);Heida, W.(1);Wisse, J.(1);Roosenboom, B.(1);Wahab, P.J.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P392: Body mass index has no effect on treatment response in Crohn's disease patients with moderate disease activity who receive adalimumab
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

K. Soufleris*1, K. Fasoulas1, N. Kafalis1, G. Lazaraki1, D. Tzilves1

Created: Friday, 22 February 2019, 9:41 AM
P392: Comparison of dietary nutrient and food additive intake between patients with moderately active ulcerative colitis, healthy stool donors and the general Australian population
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Costello S.*1,2,3, Mashei C.3, Bryant R.2,3, Katsikeros R.3, Waters O.4, Makanyanga J.4, Hughes P.2, Conlon M.5, Roberts-Thomson I.1,2, Andrews J.2,3

Created: Wednesday, 20 February 2019, 10:36 AM
P392: Comprehensive video capsule endoscopy-based monitoring predicts short and long-term risk of disease flares in small bowel Crohn’s disease: A prospective cohort study
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Ben-Horin1*, A. Lahat1, M.M. Amitai2, E. Klang2, D. Yablecovitch1, S. Neuman1, N. Levhar1, L. Selinger1, M. Bubis1, O. Picard1, D. Turner3, S. Odes4, H. Yanai5, Y. Chowers6, I. Dotan5, U. Kopylov1, R. Eliakim1

Created: Thursday, 21 February 2019, 9:14 AM
P392: Risk factors for postoperative recurrence after ileocolic resection for Crohn's Disease: long-term results from a population-based cohort.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: van Renterghem, A.(1)*;van der Holst, A.(1);van Kuijk, S.(2);Pierik, M.(3);Belgers, E.(4);Romberg-Camps, M.(5);Jeuring, S.(3);Demandt, D.(1);Stassen, L.(1);
Created: Friday, 14 July 2023, 11:05 AM
P392: To study the prevalence of depression and anxiety in patients of Inflammatory Bowel Disease (IBD) and the efficacy of psychopharmacotherapy in these patients: A pilot study
Year: 2022
Source: ECCO'22
Authors: Patel, A.(1);Joshi, H.(1);Wagh, A.(1);Bhatt, C.(1);
Created: Friday, 11 February 2022, 3:52 PM
P393 Patient and physician perspectives on the management of inflammatory bowel disease: Role of steroids in the context of biologic therapy
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Afzali1, A. Armuzzi2, Y. Bouhnik3, B. Bressler4, A. Hart5, D. Rubin6, M. Sans7, B. Siegmund8, D. Sninsky9

Created: Thursday, 30 January 2020, 10:12 AM
P393: Effect of filgotinib on anaemia in patients with Ulcerative Colitis in SELECTION
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Loveikyte, R.(1)*;de Haas, A.(2);Oortwijn, A.(3);Eskens, B.(3);Jamoul, C.(4);Muller, K.(4);van der Meulen-de Jong, A.(5);
Created: Friday, 14 July 2023, 11:05 AM
P393: Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Ustekinumab for acute severe colitis.
Year: 2022
Source: ECCO'22
Authors: Veyrard, P.(1);Pellet, G.(2);Laharie, D.(2);Nachury, M.(3);juillerat, P.(4);Altwegg, R.(5);Nancey, S.(6);Fumery, M.(7);Allez, M.(8);Tran minh, M.L.(9);Roblin, X.(10);
Created: Friday, 11 February 2022, 3:52 PM
P393: Evaluation of pharmacokinetic profiles of SB2 as a biosimilar of reference infliximab
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Shin D., Kang J.W., Park S., Lee Y., Lee S.

Created: Wednesday, 20 February 2019, 10:36 AM
P393: Investigation of Crohn’s disease patients receiving anti-TNF α therapy after surgery for intestinal stenosis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

T. Kuriyama*, B. Iizuka, H. Kashiwagi, T. Hara, A. Ito, T. Omori, M. Yonezawa, K. Tokushige

Created: Friday, 22 February 2019, 9:49 AM
P393: Long-term prediction of infliximab response using CD-62L shedding assay: Longitudinal data from 5-year study in inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

J. Macpherson1, F. Bravo2, P. Andrew1, E. Slack1, N. Patuto1, J. Cahenzli1, K.D. McCoy1, A.J. Macpherson2, P. Juillerat1,2*

Created: Thursday, 21 February 2019, 9:14 AM